Neuronetics, Inc. (STIM): Price and Financial Metrics
STIM Stock Summary
- STIM's went public 2.82 years ago, making it older than merely 7.4% of listed US stocks we're tracking.
- As for revenue growth, note that STIM's revenue has grown -21.41% over the past 12 months; that beats the revenue growth of merely 18.51% of US companies in our set.
- In terms of volatility of its share price, STIM is more volatile than 93.4% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Neuronetics Inc, a group of peers worth examining would be AXGN, PWFL, VAPO, LNN, and CHFS.
- STIM's SEC filings can be seen here. And to visit Neuronetics Inc's official web site, go to www.neurostar.com.
STIM Stock Price Chart Interactive Chart >
STIM Price/Volume Stats
|Current price||$11.31||52-week high||$22.43|
|Prev. close||$11.54||52-week low||$1.70|
|Day high||$11.93||Avg. volume||481,874|
|50-day MA||$14.17||Dividend yield||N/A|
|200-day MA||$9.16||Market Cap||291.05M|
Neuronetics, Inc. (STIM) Company Bio
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company’s NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood. Neuronetics, Inc. was founded in 2003 and is based in Malvern, Pennsylvania.
STIM Latest News Stream
|Loading, please wait...|
STIM Latest Social Stream
View Full STIM Social Stream
Latest STIM News From Around the Web
Below are the latest news stories about Neuronetics Inc that investors may wish to consider to help them evaluate STIM as an investment opportunity.
MALVERN, Pa., April 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release first quarter financial and operating results prior to market open on Tuesday, May 4, 2021. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via a webcast on the Company’s investor relations website at ir.neuronetics.com. To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international call...
MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the appointment of Robert A. Cascella to its Board of Directors, effective immediately. Following his appointment, the Neuronetics’ Board of Directors now has eight members. “I am very pleased to have a leader of Rob’s quality and experience join Neuronetics’ Board of Directors,” said Keith Sullivan, President and Chief Executive Officer of Neuronetics, Inc. “His history of value creation in healthcare uniquely qualifies him to help guide Neuronetics as we continue to build upon our market leadership posit...
Neuronetics, Inc. (NASDAQ:STIM) Full-Year Results: Here's What Analysts Are Forecasting For This Year
A week ago, Neuronetics, Inc. ( NASDAQ:STIM ) came out with a strong set of annual numbers that could potentially lead...
Company focuses on driving clinical development for NeuroStar® Advanced Therapy System for mental healthMALVERN, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced Cory Anderson has been appointed the company’s Vice President, Clinical Affairs and Medical Operations effective as of March 1. “I am excited to welcome Cory to the team and know he’ll make an impact quickly,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics, Inc. “We’re laser focused on driving clinical innovation to ensure the millions suffering from depression and other con...
Good morning, and thank you for joining us for Neuronetics' fourth-quarter 2020 conference call. Joining me on today's call are Neuronetics president and chief executive officer, Keith Sullivan; and chief financial officer, Steve Furlong.
STIM Price Returns